Literature DB >> 31533878

Notification of relapse and other previously treated tuberculosis in the 52 health districts of South Africa.

F M Marx1, T Cohen2, C Lombard3, A C Hesseling1, S S Dlamini4, N Beyers1, P Naidoo1.   

Abstract

OBJECTIVE: To investigate the extent to which relapse and other previously treated tuberculosis (TB) contribute to the notified TB burden in South Africa.
DESIGN: We conducted an ecological analysis at the level of the 52 South African health districts using national electronic TB register data. We included all bacteriologically confirmed TB cases treated for presumed drug-susceptible TB in 2011. Treatment history information was based on recorded patient categories (new vs. retreatment).
RESULTS: Relapse and other previously treated TB cases constituted between 7.6% and 40% (median 17%, interquartile range 12-22) of all bacteriologically confirmed TB cases in the 52 South African districts. Multivariable analysis suggested that districts with higher proportions of previously treated TB cases had higher TB case notification rates (P < 0.001), lower estimates of antenatal human immunodeficiency virus (HIV) prevalence in the district population (P < 0.001) as well as lower HIV co-infection rates (P < 0.001) among new TB cases.
CONCLUSION: Relapse and other previously treated TB cases contributed substantially to the notified TB burden in several South African health districts, particularly those with high case notification rates and lower antenatal HIV prevalence. Additional efforts to prevent TB among previously treated people, such as strengthening treatment monitoring and/or secondary preventive therapy, should be considered.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31533878     DOI: 10.5588/ijtld.18.0609

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  2 in total

1.  Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.

Authors:  Florian M Marx; Ted Cohen; Nicolas A Menzies; Joshua A Salomon; Grant Theron; Reza Yaesoubi
Journal:  Lancet Glob Health       Date:  2020-09       Impact factor: 26.763

2.  The absence of evidence of cure is not a risk for recurrent TB among patients treated for TB.

Authors:  L Mantshonyane; B Kgwaadira; R Gross
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 3.427

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.